Stay updated with breaking news from Mobile Android. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed.Longer follow-up is needed to examine the duration of treatment response in this patient population, according to researchers of the study, reported at ASCO
CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.Data from a real-world analysis revealed some disparities in objective and complete response rates but no statistically significant differences in measures of treatment durability for
CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.The findings of the randomized phase 3 noninferiority trial, presented at ASCO Annual Meeting, suggested concurrent chemotherapy (CCRT) could be safely
Among kidney transplant recipients with uncontrolled gout, pegloticase showed sustained decreased serum urate levels, according to findings presented at the American Transplant Congress.Patients also showed pain relief and decreased disability without worsening kidney function.
More than half of a cohort of patients with rheumatic or musculoskeletal diseases reported experiencing some post-traumatic stress outcomes during the COVID-19 pandemic, according to data presented at the EULAR 2022 Congress.